29% of infants immunized against RSV in 2023 to 2024 season

Total, 29% of infants born throughout October 2023 to March 2024 had been immunized in opposition to respiratory syncytial virus (RSV) throughout the 2023 to 2024 respiratory virus season, in response to analysis published within the Aug. 21 challenge of the U.S. Facilities for Illness Management and Prevention Morbidity and Mortality Weekly Report.

Ellen O. Boundy, Sc.D., from the CDC in Atlanta, and colleagues estimated toddler RSV immunization protection by summing the entire variety of infants who acquired nirsevimab and the variety of girls of childbearing age who acquired an RSV vaccine in 33 U.S. states and the District of Columbia (DC), divided by the entire variety of reside births.

The researchers estimated that 29% of infants born throughout October 2023 to March 2024 had been immunized in opposition to RSV throughout the 2023 to 2024 respiratory virus season throughout 33 states and DC, together with 19% and 10% by way of toddler receipt of nirsevimab and maternal RSV vaccination, respectively. By state, toddler RSV immunization protection by way of nirsevimab or maternal vaccination ranged from an estimated 11% to 53%. Thirty-eight p.c of infants who acquired nirsevimab acquired it throughout the first week of life.

“Further efforts are wanted to extend toddler safety in opposition to extreme RSV by way of maternal or toddler immunization,” the authors write.

Copyright © 2025 HealthDay. All rights reserved.